Discovering Synergistic Compounds with BYL-719 in PI3K Overactivated Basal-like PDXs.
David C Boyd, Emily K Zboril, Amy L Olex, Tess J Leftwich, Nicole S Hairr, Holly A Byers, Aaron D Valentine, Julia E Altman, Mohammad A Alzubi, Jacqueline M Grible, Scott A Turner, Andrea Ferreira-Gonzalez, Mikhail G Dozmorov, J Chuck Harrell
Author Information
David C Boyd: Department of Pathology, Virginia Commonwealth University, Richmond, VA 23298, USA.
Emily K Zboril: Department of Pathology, Virginia Commonwealth University, Richmond, VA 23298, USA.
Amy L Olex: C. Kenneth and Dianne Wright Center for Clinical and Translational Research, Virginia Commonwealth University, Richmond, VA 23298, USA. ORCID
Tess J Leftwich: Department of Pathology, Virginia Commonwealth University, Richmond, VA 23298, USA.
Nicole S Hairr: Department of Pathology, Virginia Commonwealth University, Richmond, VA 23298, USA. ORCID
Holly A Byers: Department of Pathology, Virginia Commonwealth University, Richmond, VA 23298, USA.
Aaron D Valentine: Department of Pathology, Virginia Commonwealth University, Richmond, VA 23298, USA. ORCID
Julia E Altman: Department of Pathology, Virginia Commonwealth University, Richmond, VA 23298, USA.
Mohammad A Alzubi: Department of Pathology, Virginia Commonwealth University, Richmond, VA 23298, USA.
Jacqueline M Grible: Department of Pathology, Virginia Commonwealth University, Richmond, VA 23298, USA.
Scott A Turner: Department of Pathology, Virginia Commonwealth University, Richmond, VA 23298, USA.
Andrea Ferreira-Gonzalez: Department of Pathology, Virginia Commonwealth University, Richmond, VA 23298, USA.
Mikhail G Dozmorov: Department of Pathology, Virginia Commonwealth University, Richmond, VA 23298, USA. ORCID
J Chuck Harrell: Department of Pathology, Virginia Commonwealth University, Richmond, VA 23298, USA. ORCID
Basal-like triple-negative breast cancer (TNBC) tumor cells are difficult to eliminate due to resistance mechanisms that promote survival. While this breast cancer subtype has low PIK3CA mutation rates when compared to estrogen receptor-positive (ER+) breast cancers, most basal-like TNBCs have an overactive PI3K pathway due to gene amplification or high gene expression. BYL-719 is a PIK3CA inhibitor that has been found to have low drug-drug interactions, which increases the likelihood that it could be useful for combinatorial therapy. Alpelisib (BYL-719) with fulvestrant was recently approved for treating ER+ breast cancer patients whose cancer had developed resistance to ER-targeting therapy. In these studies, a set of basal-like patient-derived xenograft (PDX) models was transcriptionally defined with bulk and single-cell RNA-sequencing and clinically actionable mutation profiles defined with Oncomine mutational profiling. This information was overlaid onto therapeutic drug screening results. BYL-719-based, synergistic two-drug combinations were identified with 20 different compounds, including everolimus, afatinib, and dronedarone, which were also found to be effective at minimizing tumor growth. These data support the use of these drug combinations towards cancers with activating PIK3CA mutations/gene amplifications or PTEN deficient/PI3K overactive pathways.
